Seven Interviews, One Message: Experts Agree the Future of NAMs is About Implementation

At the 3DCC Conference held in Goa in January 2026, I had the opportunity to be one of the interviewees for an interview series filmed onsite and focused on New Approach Methodologies (NAMs), covering topics including organoids, organ-on-chip technologies, artificial intelligence (AI), regulatory science, liver biology, and animal-free research.
Upon review of the interviews, I was pleasantly surprised by the level of agreement given the diverse backgrounds of the interviewees. A consistent message emerged: the next phase of NAMs will depend on validation, standardization, and implementation. The challenge is increasingly not simply proving that the technologies work but rather demonstrating that they are reliable, reproducible, and applicable to the scientific question being asked.
Seven Perspectives on a Shared Challenge
Dr. Marcin Krzykawsk, CEO & Cofounder, REAL Research: Scientific innovation creates possibilities, but trust, reproducibility, and scalability determine adoption.
Link to video: https://www.youtube.com/watch?v=XyKbI1SgA0o
Thomas Hartung, Professor, Johns Hopkins Bloomberg School of Public Health: Animal testing was never a true gold standard; AI and human-relevant biology offer a fundamentally better future.
Link to video: https://www.youtube.com/watch?v=7VM2JwCvf68
Dr. Savneet Kaur, Assistant Professor, Guru Gobind Singh College for Women : Good science starts with asking the right biological question, ideally informed by a clinical need.
Clive Roper BSc PhD CBiol CSci ERT FRSB, Director, Roper Toxicology Consulting Limited : Model selection must begin with the scientific question being asked and a clearly defined context of use.
Link to video: https://www.youtube.com/watch?v=zxL7TcGthp4
Dr. Charu Chandrasekera, Founder & President, Canadian Institute for Animal-Free Science: Human-relevant scientific approaches are essential to address questions animal models often fail to answer.
Link to video: https://www.youtube.com/watch?v=9jAODgv6L9I
Dr. Carlo Paggi, Co-founder, chiron: Organ-on-chip technology will only succeed if it becomes simple, usable, and accessible to everyday laboratory scientists.
Maurice Whelan, Deputy Director for Health & Food, Head of Systems Toxicology Unit and the EU Reference Lab for alternatives to animal testing (EURL ECVAM), European Commission, Joint Research Centre (JRC): The future of NAMs depends less on new ideas and more on validation, standards, and regulatory implementation.
Key Takeaways from the Interviews
For many years, discussions around NAMs were dominated by comparisons with animal testing. This remains important, but the tone of the conversation has clearly shifted. Whether speaking from the perspective of regulatory science, translational medicine or technology development, the emphasis is increasingly on human relevance rather than animal replacement. The key question is not what replaces an animal study, but how we generate evidence that is more predictive of human biology, human disease, and human responses. In many ways this represents a maturation of the field.
Start With The Question
As a toxicologist, what I found of particular interest was that regardless of whether the interviewee came from a regulatory, academic, or industry background, they all returned to the same principle that understanding the question is more important than choosing the technology. The emphasis increasingly on human relevance: how can we generate evidence that better reflects human biology, disease, and responses? Animal replacement and ethical considerations remain important, while scientific performance provides the compelling reason for adoption. There is no single technology that answers every question. Organoids, organ-on-chip platforms, advanced cell culture systems, computational models, and AI all have roles, but their value depends on how they are used.
Build Confidence Through Reliable Performance
Innovation alone does not establish confidence. Regulators, industry scientists, and other decision makers need evidence that a model produces reliable, reproducible results that can transfer across laboratories, operators, and settings. Standardisation supports that confidence, but it should not be confused with uniformity. Laboratories do not need to use the same technology. They do need agreed quality standards and performance expectations so that different approaches can be evaluated consistently.
Usability and scalability also matter. A promising model must be practical to operate, accessible to laboratory scientists, and capable of delivering consistent performance beyond its original development setting.
Make Implementation Part of Development
Regulatory considerations should inform technology development from the outset. A clearly defined regulatory context of use and early dialogue can help developers understand the evidence required, while allowing regulators to become familiar with emerging approaches before formal submissions.
Collaboration is equally important. Academia contributes new models and mechanistic understanding. Industry brings expertise in manufacturing, quality systems, and scale. Clinicians help connect development to patient needs, while regulators clarify expectations for decision-making. Moving beyond proof of concept requires these perspectives to work together.
AI offers further opportunities to analyse data, identify patterns, and support decisions. Its value, however, depends on the quality and relevance of the data underpinning it. Better computational tools and better human-relevant biology must advance together.
Measure Success Through Better Decisions
Taken together, these conversations suggest that NAMs are entering a more mature phase. Demonstrating scientific possibility remains important, but greater attention is now turning to dependable performance and practical adoption. Success will be measured by whether these approaches improve research, safety assessment, and human health. That requires more than sophisticated technology: it requires evidence, trust, and a clear route into everyday use.
The shared message is clear: The future of NAMs depends on turning innovation into reliable implementation. #NewApproachMethodologies #NAMs #MethodValidation #RegulatoryScience #HumanRelevantScience #Toxicology




Comments